Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia
Esophageal Neoplasms, Esophagus Stenosis
About this trial
This is an interventional prevention trial for Esophageal Neoplasms focused on measuring Esophageal stenosis, Esophageal squamous cell neoplasia, Endoscopic radiofrequency ablation, Prednisolone
Eligibility Criteria
Inclusion Criteria: Histology from endoscopic biopsies showed squamous intraepithelial neoplasia without stromal invasion; No lymph node metastasis on endoscopic ultrasound or computed tomography; Magnifying endoscopy showed the intraepithelial papillary capillary loop as type B1 pattern, according to the classification of the microvascular architecture of superficial esophageal carcinoma. Exclusion Criteria: A prior history of endoscopic resection, radiation therapy or esophagectomy for esophageal cancer; A stricture that prevented the passage of a therapeutic endoscope; Uncontrolled coagulopathy; Poorly controlled diabetes mellitus.
Sites / Locations
- EDA HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Administration of oral prednisolone
Oral prednisolone start at a dose of 30 mg/day on the third day after RFA, and continue for 4 weeks.